logo

Clinical Trial Results

Share

Eli Lilly and Co. (LLY) said Thursday that its neutralizing antibody Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities in the BLAZE-2 trial. The risk was reduced by up to 80 percent, the company noted. Bamlanivimab...

Shares of Lipocine Inc. (LPCN) are rising almost 8 percent in Tuesday's pre-market activity after the biopharmaceutical company reported positive topline results from its LiFT Phase 2 clinical study, investigating LPCN 1144 in biopsy-confirmed non-cirrhotic non-alcoholic steatohepatitis or NASH male...

Biopharmaceutical company Ultragenyx Pharmaceutical Inc. (RARE) on Friday announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 studies of DTX401, an investigational adeno-associated virus or AAV gene therapy for Glycogen Storage Disease Type Ia...

AbbVie (ABBV) said Risankizumab or Skyrizi has demonstrated significant improvements in clinical remission and endoscopic response in two phase 3 induction studies in patients with crohn's disease. The company noted hat a significantly greater proportion of patients with Crohn's disease treated with...

Alnylam Pharmaceuticals, Inc. (ALNY) said Thursday that the HELIOS-A Phase 3 study of vutrisiran, met its primary and both secondary endpoints at nine months in patients with hATTR amyloidosis with polyneuropathy. Vutrisiran is an investigational RNAi therapeutic in development for the treatment...

Inovio Pharmaceuticals Inc. (INO) on Wednesday announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. The company said that a reduction of 25 percent or more in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial...

RedHill Biopharma Ltd. (RDHL) said that preliminary data from its U.S. Phase 2 study with orally-administered opaganib in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals. The randomized, double-blind, placebo-controlled U.S. Phase 2 proof-of-concept...

Axsome Therapeutics Inc. (AXSM) announced positive efficacy and safety results from phase 3 movement long-term trial of AXS-07 in the acute treatment of migraine. According to the company, treatment with AXS-07, rapidly, substantially, and durably relieved migraine pain and associated symptoms in...

Regeneron Pharmaceuticals, Inc. (REGN) announced Tuesday encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. The analysis focuses on patients who had not yet...

Biopharmaceutical company Bristol Myers Squibb Co. (BMY) said Wednesday that following a routine review of the CheckMate -548 Phase 3 trial by an independent data monitoring committee or DMC, the company was informed that based on the number of events to date, the study will not meet its primary endpoint...

Amgen (AMGN) and AstraZeneca announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid dose, without loss of asthma control, with tezepelumab compared to placebo. The safety profile of tezepelumab in the trial was consistent...

Follow RTT